|
1
|
Laflamme MA and Murry CE: Heart
regeneration. Nature. 473:326–335. 2011.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Szummer K, Jernberg T and Wallentin L:
From early pharmacology to recent pharmacology interventions in
acute coronary syndromes: JACC State-of-the-Art review. J Am Coll
Cardiol. 74:1618–1636. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Hausenloy DJ and Yellon DM: Myocardial
ischemia-reperfusion injury: A neglected therapeutic target. J Clin
Invest. 123:92–100. 2013.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Fan ZX and Yang J: The role of microRNAs
in regulating myocardial ischemia reperfusion injury. Saudi Med J.
36:787–793. 2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Shimokawa H, Sunamura S and Satoh K:
RhoA/Rho-kinase in the cardiovascular system. Circ Res.
118:352–366. 2016.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Zhou Q and Liao JK: Rho kinase: An
important mediator of atherosclerosis and vascular disease. Curr
Pharm Des. 15:3108–3115. 2009.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Zhang J, Xu DL, Liu XB, Bi SJ, Zhao T, Sui
SJ, Ji XP and Lu QH: Darapladib, a lipoprotein-associated
phospholipase A2 inhibitor, reduces rho kinase activity in
atherosclerosis. Yonsei Med J. 57:321–327. 2016.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Patel P, Parikh M, Shah H and Gandhi T:
Inhibition of RhoA/Rho kinase by ibuprofen exerts cardioprotective
effect on isoproterenol induced myocardial infarction in rats. Eur
J Pharmacol. 791:91–98. 2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Tanna AP and Johnson M: Rho Kinase
inhibitors as a novel treatment for glaucoma and ocular
hypertension. Ophthalmology. 125:1741–1756. 2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ocaranza MP, Moya J, Jalil JE, Lavandero
S, Kalergis AM, Molina C, Gabrielli L, Godoy I, Córdova S, Castro
P, et al: Rho-kinase pathway activation and apoptosis in
circulating leucocytes in patients with heart failure with reduced
ejection fraction. J Cell Mol Med. 24:1413–1427. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Fazakas C, Nagaraj C, Zabini D, Végh AG,
Marsh LM, Wilhelm I, Krizbai IA, Olschewski H, Olschewski A and
Bálint Z: Rho-kinase inhibition ameliorates Dasatinib-induced
endothelial dysfunction and pulmonary hypertension. Front Physiol.
9(537)2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Bao W, Hu E, Tao L, Boyce R, Mirabile R,
Thudium DT, Ma XL, Willette RN and Yue TL: Inhibition of Rho-kinase
protects the heart against ischemia/reperfusion injury. Cardiovasc
Res. 61:548–558. 2004.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zhang J, Li XX, Bian HJ, Liu XB, Ji XP and
Zhang Y: Inhibition of the activity of Rho-kinase reduces
cardiomyocyte apoptosis in heart ischemia/reperfusion via
suppressing JNK-mediated AIF translocation. Clin Chim Acta.
401:76–80. 2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang J, Bian HJ, Li XX, Liu XB, Sun JP,
Li N, Zhang Y and Ji XP: ERK-MAPK signaling opposes rho-kinase to
reduce cardiomyocyte apoptosis in heart ischemic preconditioning.
Mol Med. 16:307–315. 2010.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Li Y, Zhu W, Tao J, Xin P, Liu M, Li J and
Wei M: Fasudil protects the heart against ischemia-reperfusion
injury by attenuating endoplasmic reticulum stress and modulating
SERCA activity: The differential role for PI3K/Akt and JAK2/STAT3
signaling pathways. PLoS One. 7(e48115)2012.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Jiang ZH, Zhang TT and Zhang JF:
Protective effects of fasudil hydrochloride post-conditioning on
acute myocardial ischemia/reperfusion injury in rats. Cardiol J.
20:197–202. 2013.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang YS, Tang LJ, Tu H, Wang SJ, Liu B,
Zhang XJ, Li NS, Luo XJ and Peng J: Fasudil ameliorates the
ischemia/reperfusion oxidative injury in rat hearts through
suppression of myosin regulatory light chain/NADPH oxidase 2
pathway. Eur J Pharmacol. 822:1–2. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Huang YY, Wu JM, Su T, Zhang SY and Lin
XJ: Fasudil, a rho-kinase inhibitor, exerts cardioprotective
function in animal models of myocardial ischemia/reperfusion
injury: A meta-analysis and review of preclinical evidence and
Possible Mechanisms. Front Pharmacol. 9(1083)2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sirtori CR: The pharmacology of statins.
Pharmacol Res. 88:1–3. 2014.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Istvan ES and Deisenhofer J: Structural
mechanism for statin inhibition of HMG-CoA reductase. Science.
292:1160–1164. 2001.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Oesterle A, Laufs U and Liao JK:
Pleiotropic effects of statins on the cardiovascular system. Circ
Res. 120:229–243. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Tramontano AF, O'Leary J, Black AD,
Muniyappa R, Cutaia MV and El-Sherif N: Statin decreases
endothelial microparticle release from human coronary artery
endothelial cells: Implication for the Rho-kinase pathway. Biochem
Biophys Res Commun. 320:34–38. 2004.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yamanouchi D, Banno H, Nakayama M,
Sugimoto M, Fujita H, Kobayashi M, Kuwano H and Komori K:
Hydrophilic statin suppresses vein graft intimal hyperplasia via
endothelial cell-tropic Rho-kinase inhibition. J Vasc Surg.
42:757–764. 2005.PubMed/NCBI View Article : Google Scholar
|
|
24
|
McNeish AJ, Jimenez-Altayo F, Cottrell GS
and Garland CJ: Statins and selective inhibition of Rho kinase
protect small conductance calcium-activated potassium channel
function (K(Ca)2.3) in cerebral arteries. PLoS One.
7(e46735)2012.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Ma MM, Li SY, Wang M and Guan YY:
Simvastatin attenuated cerebrovascular cell proliferation in the
development of hypertension through Rho/Rho-kinase pathway. J
Cardiovasc Pharmacol. 59:576–582. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Narumiya S and Thumkeo D: Rho signaling
research: History, current status and future directions. FEBS Lett.
592:1763–1776. 2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nagata S: Apoptosis and clearance of
apoptotic cells. Annu Rev Immunol. 36:489–517. 2018.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Li M, Liu Y, Dutt P, Fanburg BL and Toksoz
D: Inhibition of serotonin-induced mitogenesis, migration, and ERK
MAPK nuclear translocation in vascular smooth muscle cells by
atorvastatin. Am J Physiol Lung Cell Mol Physiol. 293:L463–L471.
2007.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Ridker PM, Danielson E, Fonseca FA, Genest
J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ,
MacFadyen JG, et al: Rosuvastatin to prevent vascular events in men
and women with elevated C-reactive protein. N Engl J Med.
359:2195–2207. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rawlings R, Nohria A, Liu PY, Donnelly J,
Creager MA, Ganz P, Selwyn A and Liao JK: Comparison of effects of
rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase
activity in caucasian men with a previous atherosclerotic event. Am
J Cardiol. 103:437–441. 2009.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sun T, Zhang HJ, Krittanawong C, Wang S,
Tao Y, Li Z, Yin Q, Zhang D, Wang Q, Huang J, Zhang J, Li Z and
Cheng Y: Acute atorvastatin treatment restores the cardioprotective
effects of ischemic postconditioning in hyperlipidemic rats.
Oncotarget. 8:55187–55193. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
El Desoky ES, Hassan AKM, Salem SY, Fadil
SA and Taha AF: Cardioprotective effect of atorvastatin alone or in
combination with remote ischemic preconditioning on the biochemical
changes induced by ischemic/reperfusion injury in a mutual
prospective study with a clinical and experimental animal arm. Int
J Cardiol. 222:866–873. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Rohilla A, Ahmad A, Khan MU and Khanam R:
A comparative study on the cardioprotective potential of
atorvastatin and simvastatin in hyperhomocysteinemic rat hearts.
Eur J Pharmacol. 764:48–54. 2015.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ye YC, Zhao XL and Zhang SY: Use of
atorvastatin in lipid disorders and cardiovascular disease in
Chinese patients. Chin Med J. 128:259–266. 2015.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sydow K and Munzel T: ADMA and oxidative
stress. Atheroscler Suppl. 4:41–51. 2003.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Chatterjee A, Black SM and Catravas JD:
Endothelial nitric oxide (NO) and its pathophysiologic regulation.
Vascular Pharmacol. 49:134–140. 2008.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lunder M, Ziberna L, Janić M, Jerin A,
Skitek M, Sabovič M and Drevenšek G: Low-dose atorvastatin,
losartan, and particularly their combination, provide
cardiovascular protection in isolated rat heart and aorta. Heart
Vessels. 28:246–254. 2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Takemoto M, Sun J, Hiroki J, Shimokawa H
and Liao JK: Rho-kinase mediates hypoxia-induced downregulation of
endothelial nitric oxide synthase. Circulation. 106:57–62.
2002.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Rikitake Y, Kim HH, Huang Z, Seto M, Yano
K, Asano T, Moskowitz MA and Liao JK: Inhibition of Rho kinase
(ROCK) leads to increased cerebral blood flow and stroke
protection. Stroke. 36:2251–2257. 2005.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Wang Q, Guo YZ, Zhang YT, Xue JJ, Chen ZC,
Cheng SY, Ou MD, Cheng KL and Zeng WJ: The Effects and mechanism of
atorvastatin on pulmonary hypertension due to left heart disease.
PLoS One. 11(e0157171)2016.PubMed/NCBI View Article : Google Scholar
|
|
41
|
An L, An S, Jia Z, Wang H, Yang Z, Xu C,
Teng X, Wang J, Liu X, Cao Q and Wang S: Atorvastatin improves left
ventricular remodeling and cardiac function in rats with congestive
heart failure by inhibiting RhoA/Rho kinase-mediated endothelial
nitric oxide synthase. Exp Ther Med. 17:960–966. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhang J, Liu XB, Cheng C, Xu DL, Lu QH and
Ji XP: Rho-kinase inhibition is involved in the activation of
PI3-kinase/Akt during ischemic-preconditioning-induced
cardiomyocyte apoptosis. Int J Clin Exp Med. 7:4107–4114.
2014.PubMed/NCBI
|
